Source: International Congress 2019 – New towards old therapies in airway diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Maltais (Québec, QC, Canada), I. Naya (Brentford, Middlesex, United Kingdom), E. Kerwin (Medford, OR, United States of America), L. Bjermer (Lund, Sweden), I. Boucot (Brentford, Middlesex, United Kingdom), P. Jones (Brentford, Middlesex, United Kingdom), L. Tombs (Uxbridge, Middlesex, United Kingdom), D. Lipson (Collegeville, PA, United States of America), C. Compton (Brentford, Middlesex, United Kingdom), C. Vogelmeier (Marburg, Germany). Late Breaking Abstract - Influence of salbutamol use on symptomatic outcomes with maintenance bronchodilators: a pre-specified analysis of the EMAX trial. 2108

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Cost effectiveness of as-needed budesonide/formoterol vs low-dose ICS maintenance therapy in mild asthma patients: A UK perspective Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 Late Breaking Abstract - Difference in clinical outcomes between smoking and non-smoking asthma patients who initiated an ICS or ICS/LABA treatment Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Late Breaking Abstract - Impact of maintenance and reliever therapy (MART)-focused asthma guideline on SABA prescriptions Source: Virtual Congress 2021 – Highlights for primary care in 2021 Year: 2021 Late Breaking Abstract - Short-term and maintenance oral corticosteroid use for German patients with asthma Source: International Congress 2019 – Powerful cohort studies with/without lung function Year: 2019 Late Breaking Abstract - Impact of ICS/LABA and LABA/LAMA FDCs on lung function and exacerbation of COPD: a network meta-analysis Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Late Breaking Abstract - The impact of regular bisoprolol on recovery with salbutamol in asthma; a double-blind randomised controlled trial Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Evaluating cardiac safety of tiotropium in patients with COPD: Combined analysis of Holter-ECG data from four trials Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Late Breaking Abstract - Corticosteroid optimisation in severe asthma using composite biomarkers to adjust dose versus a symptom/risk-based algorithm Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020 Late Breaking Abstract - Reduction of COPD exacerbations with extrafine single inhaler triple therapy: post-hoc analysis by exacerbation treatment of the TRIBUTE study Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 Late Breaking Abstract - Open-label trial of budesonide/formoterol reliever therapy in mild asthma Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019 Late Breaking Abstract - A randomized clinical study to assess the impact of budesonide/formoterol (BUD/FM) pMDI medication reminders on adherence in COPD patients Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018 Late Breaking Abstract - Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017 Late Breaking Abstract - Can a self-management plan, which includes a four-fold increase in inhaled corticosteroid dose, reduce severe asthma exacerbations: a randomised, pragmatic trial. Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017 Late Breaking Abstract - Assessment of physical functioning and handling with Tiotropium/Olodaterol (T/O) in patients with COPD requiring long-acting dual bronchodilation in an Italian cohort of patients. Source: International Congress 2019 – COPD treatment: cohorts and real-world studies Year: 2019 Late Breaking Abstract - IMPACT study — single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: healthcare resource utilization and costs — UK Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 Late Breaking Abstract - Inhaled indacaterol does not affect lung function or symptoms in lymphangioleiomyomatosis: a double blind placebo controlled cross-over trial Source: International Congress 2017 – From idiopathic pulmonary fibrosis (IPF) to rare diseases Year: 2017 Late Breaking Abstract - Prolonged azithromycin maintenance treatment in patients with COPD, a follow-up of the COLUMBUS trial Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 Late Breaking Abstract - RECEIVER trial: sustained use and improved outcomes with digitally supported COPD co-management Source: Virtual Congress 2021 – E-health for COVID-19 Year: 2021 Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013